198 related articles for article (PubMed ID: 11270803)
1. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
[TBL] [Abstract][Full Text] [Related]
2. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
Trausch B; Oertel R; Richter K; Gramatté T
Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
[TBL] [Abstract][Full Text] [Related]
3. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
5. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
Wetterich U; Spahn-Langguth H; Mutschler E; Terhaag B; Rösch W; Langguth P
Pharm Res; 1996 Apr; 13(4):514-22. PubMed ID: 8710739
[TBL] [Abstract][Full Text] [Related]
6. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
7. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Juan H; Terhaag B; Cong Z; Bi-Kui Z; Rong-Hua Z; Feng W; Fen-Li S; Juan S; Jing T; Wen-Xing P
Eur J Clin Pharmacol; 2007 Jul; 63(7):663-8. PubMed ID: 17468862
[TBL] [Abstract][Full Text] [Related]
8. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
9. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
10. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
Payton CD; Fox JG; Pauleau NF; Boulton-Jones JM; Ioannides C; Johnston A; Thomas P
Eur Heart J; 1987 Dec; 8 Suppl M():15-22. PubMed ID: 2897297
[TBL] [Abstract][Full Text] [Related]
11. Butofilolol pharmacokinetics in chronic renal insufficiency.
Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
[TBL] [Abstract][Full Text] [Related]
12. Grapefruit juice ingestion significantly reduces talinolol bioavailability.
Schwarz UI; Seemann D; Oertel R; Miehlke S; Kuhlisch E; Fromm MF; Kim RB; Bailey DG; Kirch W
Clin Pharmacol Ther; 2005 Apr; 77(4):291-301. PubMed ID: 15903127
[TBL] [Abstract][Full Text] [Related]
13. High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Nguyen MA; Staubach P; Tamai I; Langguth P
Eur J Pharm Sci; 2015 Feb; 68():36-42. PubMed ID: 25486333
[TBL] [Abstract][Full Text] [Related]
14. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
16. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum.
Oertel R; Richter K; Trausch B; Berndt A; Gramatté T; Kirch W
J Chromatogr B Biomed Appl; 1994 Oct; 660(2):353-63. PubMed ID: 7866526
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
20. Interaction of talinolol and sulfasalazine in the human gastrointestinal tract.
Terhaag B; Palm U; Sahre H; Richter K; Oertel R
Eur J Clin Pharmacol; 1992; 42(4):461-2. PubMed ID: 1355428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
